Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment
- 14 June 2014
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 10 (8) , 1107-1123
Abstract
Metastatic malignant melanoma is a frequently fatal cancer. In recent years substantial therapeutic progress has occurred with the development of targeted kinase inhibitors and immunotherapeutics. Targeted therapies often result in rapid clinical benefit however responses are seldom durable. Immune therapies can result in durable disease control but responses may not be immediate. Optimal cancer therapy requires both rapid and durable cancer control and this can likely best be achieved by combining targeted therapies with immunotherapeutics. To achieve this, a detailed understanding of the immune consequences of the various kinase inhibitors, in development, clinical trial and currently used to treat melanoma is required.Keywords
This publication has 177 references indexed in Scilit:
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyInternational Journal of Cancer, 2011
- Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccinesBritish Journal of Cancer, 2011
- Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1Cellular Immunology, 2011
- In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitorsCancer Immunology, Immunotherapy, 2010
- Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-α expression in macrophages by reducing IL-10 expressionMolecular Immunology, 2009
- Activation of Akt as a Mechanism for Tumor Immune EvasionMolecular Therapy, 2009
- PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytesNature, 2000